



AlzChem Group AG

Andreas Niedermaier, CEO
Dr. Georg Weichselbaumer, CSO

November 11, 2020



DISCLAIMER



Cautionary note regarding forward-looking statements

This presentation contains forward-looking statements about the business, financial condition and earnings performance of the AlzChem Group. These statements are based on assumptions and projections resting upon currently available information and present estimates. They are subject to a multitude of uncertainties and risks. Actual business development may therefore differ materially from what has been expected. Beyond disclosure requirements stipulated by law, AlzChem does not undertake any obligation to update forward-looking statements.

Unless stipulated otherwise, all values are rounded up or down in accordance with the commercial rounding practices. Please note that differences can result from the use of rounded amounts and percentages.

AGENDA

Analyst Presentation Q3/2020



EXECUTIVE SUMMARY

BUSINESS AND FINANCIAL DETAILS

BACK-UP

HIGHLIGHTS

Summary of business development Q3/2020 Financial Report

Stable growth in
NITRALZ® business

Positive development in
Perlka® business

Bioselect® products key
contributor in Q3


Ongoing growth in
Creamino®

Lower commodity prices
support earnings

COVID-19:
stable production without
interruptions

Slow recovery of steel and
automotive business

Adjustment of sales and
EBITDA outlook



Decision to add one more line to the nitrile production unit

BASIC CHEMICALS

~12 m€

INVESTMENT (Step II.)

The additional investment will create profitable growth for the segment

In 2017, AlzChem decided to invest 7.2 million € (Step I.) into a first expansion of the NITRALZ® production plant in Trostberg (DE).

The expanded plant was commissioned in July 2019 and quickly reached nameplate capacity.

ADDITIONAL DEMAND

+50%

PRODUCTION CAPACITY

Plant expansion in special equipment and materials

Increased production capacities for NITRALZ®

TURNOVER POTENTIAL

> 10 m€



Raw materials for a variety of end markets (pharma, agro, biocides, pigments)

PRODUCTION ADVANTAGE

- Proprietary process > 50 years experience
- Sustainable, continuous, solvent free green process
- Reliable supply from the sole manufacturer outside of China – Made in Germany
- AlzChem cost and environment process differs positively from most Chinese competitors

MARKET DYNAMICS

- Creation of independent supply chain (China) for the most modern class of:
 - antihypertensives (-sartane) and
 - the biocide BIT
- Support of market growth of main Biocide (BIT)
- Growth with environmentally friendly pigments (replacement of heavy metals based pigments)

NITRALZ® APPLICATIONS



Agrochemicals



Industrial use



Pharmaceutical



Pigments



Solvents



FINANCIAL OVERVIEW Q3/2020



Key figures

AlzChem Group	Q3 2019	Q3 2020	yoy %	2019 1 - 9	2020 1 - 9	yoy %
SALES (in M€)	99.4	81.4	-18.2%	287.7	278.6	-3.1%
EBITDA (in M€)	13.6	12.0	-11.6%	41.4	41.1	-0.7%
EBITDA margin (in %)	13.6%	14.7%	+1.1 pp	14.4%	14.8%	+0.4 pp
Earnings per Share (in €)	0.49	0.37	-24.9%	1.66	1.46	-11.9%

COMMENTS

- Decrease in sales in Q3, mainly caused by declines in the market segments metallurgy and automotive
- EBITDA did not decline in the same extent as the sales figures
- EBITDA margin even increased in comparison to Q3 in 2019 and also compared to the period of Q1 – Q3 in 2019
- Higher depreciation leads to lower earnings per share

SALES ANALYSIS	DELTA Q3	DELTA 01 - 09
Volume	-17.7%	-4.8%
Price	0.3%	0.9%
Currency	-0.7%	0.1%

AGENDA

Analyst Presentation Q3/2020



EXECUTIVE SUMMARY

BUSINESS AND FINANCIAL DETAILS

BACK-UP

BASICS & INTERMEDIATES SEGMENT

Our integrated system



DESCRIPTION

The "Basics & Intermediates" segment comprises the production of **basic and intermediate products** that are marketed as independent products for example in agriculture, steel production and the automotive sector and as raw materials for the manufacture of specialty chemicals.

SELECTED PRODUCTS




NITRALZ®




BASICS & INTERMEDIATES SEGMENT

Steel and automotive weakness not fully offset by NITRALZ® and agro


SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q3	DELTA 01 - 09
Volume	-21.1%	-7.4%
Price	-1.0%	0.0%
Currency	-0.4%	+0.1%

COMMENTS

- Q3/2020 sales significantly lower than previous year
- Continued strong NITRALZ® performance based on new production capacities installed in 2019
- Positive development in Perlka® business
- Business environment in metallurgy and automotive is very difficult at the moment
- Higher EBITDA of ~6.4 M€ (previous year 4.9 M€) in the period Q1 – Q3 based on larger sales volumes of higher-value products and low raw material prices

SPECIALTY CHEMICALS SEGMENT

Our growth focus



DESCRIPTION

The "Specialty Chemicals" segment produces and sells **high-quality growth products** in the area of specialty chemicals.

SELECTED PRODUCTS

 **Creapure**®

DYHARD®

 **Dormex**®

**LIVA
DUR**®

CREAMINO


Bioselect®




SPECIALTY CHEMICALS SEGMENT

COVID-19 affects more than the automotive part of the business


SALES



EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q3	DELTA 01 - 09
Volume	-15.5%	-1.1%
Price	+1.1%	+1.3%
Currency	-1.2%	+0.1%

COMMENTS

- Sales and EBITDA YTD slightly above previous year's level
- Slowdown of Creamino® growth due to Pandemic
- High demand for pharma raw materials (Multipurpose Plants and Bioselect®)
- Creapure® volumes below last year
- DYHARD® and Nitroguanidine business are affected severely by COVID-19 pandemic (decline in demand in the automotive and renewable energies sectors)
- Q3 EBITDA is above previous year, despite significant revenue declines (cost savings and positive product mix)

OTHER & HOLDING SEGMENT

Further activities



DESCRIPTION

The "Other & Holding" segment offers **infrastructure** and **energy supply** services at our locations for the chemicals segments and for external customers.


The segment also comprises all activities that cannot be allocated to the other segments.




OTHER & HOLDING SEGMENT

Service sales largely stable with a slight downward trend


SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q3	DELTA 01 - 09
Volume	-13.2%	-7.4%
Price	+2.4%	+2.4%
Currency	0.0%	0.0%

COMMENTS


- Overall sales slightly below previous year's level
- Slightly less demand in maintenance and energy supply
- Earnings significantly affected by higher maintenance costs to modernize infrastructure

BALANCE SHEET

AlzChem Group AG (M€)




ASSETS



- Lower other non-current assets due to major capex projects in 2019 (capex below depreciation)
- Slightly positive impact from inventory optimization project
- Other current assets increased due to a higher level of cash and cash equivalents
- Deferred taxes for pension provision increased due to higher pension obligations


LIABILITIES



- Equity ratio increased from 17.9 % to 18.7 % due to positive earnings
- Higher pension provision due to decline in interest rates
- Lower other non-current liabilities because of regular repayment of long-term loans

CASHFLOW

Positive free cashflow due to strong cash inflow from ongoing operations



COMMENTS

- Strong cash inflow from ongoing operations
- Positive effect of inventory reduction on cashflow from ongoing operations
- Investing cashflow below prior year's level due to main CAPEX projects Creamino® and NITRALZ® in 2019
- Cashflow from financing activities (-14.1 M€) – main effects: scheduled repayment of bank loans (-8.9 M€), deposits of short-term financing lines (+4.0 M€), dividend payments (-7.6 M€) as well as repayment of lease liabilities (-1.4 M€)
- Previous year's cashflow from financing activities: payout of the loan (30.1 M€)

IMPLEMENTING OPERATING TARGETS

Focus on the key growth drivers

IMPLEMENTATION OF THE CREAMINO® GROWTH

ON THE WAY

- Increase number of trials worldwide
- Oversupply and weak demand in food chain
- Trials slowed down due to COVID-19
- Evonik market entry should develop the market faster

REALIZATION OF THE NEXT NITRALZ® CAPACITY EXPANSIONS

- Acquisition of customer contracts
- External financing close to finish line
- Start of construction of the plant
- Planned commissioning: end of Q2/2021

IN REALIZATION

ESTABLISH FIRST SALES OF LIVADUR®

TEST PHASE RUNNING

- Pharmacy sales very low
- Push various promotion activities (radio spots, podcasts...)
- Sales concept under review – increased focus on online sales

SUSTAINABILITY

PROJECT LAUNCHED



- Team installed
- Define and set the tone with CO₂ neutral growth
- Target of zero accidents and incidents

MANAGEMENT OF COVID-19 EFFECTS

CONSTANTLY CHALLENGES US

OUTLOOK 2020

Outlook adjustment for sales and EBITDA to stable to moderately lower



COMMENTS

- Sales are expected to be stable to slightly lower (original forecast: slightly rising to sharply rising)
- EBITDA is expected to be stable to moderately lower following sales (original forecast: stable to sharply rising)
- Creamino® ramp-up delayed due to inefficiency of meat markets
- Continued low demand for steel at least for Q4
- Further stable growth of NITRALZ® business
- Significant business expansion in the pharmaceutical industry
- Slower than expected recovery of the global economy due to the worries caused by COVID -19

FINANCIAL CALENDAR

Upcoming dates



2020	NOV 17	Deutsches Eigenkapitalforum (virtual)
2020	NOV 30	Berenberg European Conference Pennyhill, London
2020	DEC 8/9	MKK – Münchner Kapitalmarkt Konferenz
2021	MAR 19	Annual Report 2020
2021	MAY 6	Quarterly Statement 1st Quarter 2021
2021	MAY 12	Annual General Meeting 2021
2021	AUG 5	Half-Year Financial Report 2021
2021	NOV 11	Quarterly Statement 3rd Quarter 2021





1,630

EMPLOYEES
(PY 1,587)

M€
~279
SALES
(PY ~288)

M€
~41
EBITDA
(PY ~41)


M€
~34
OPERATING
CASHFLOW
(PY ~26)



ALZCHEM
PRODUCTS
ARE SOLD
WORLDWIDE

INNOVATION SINCE

1908



*All financial indicators relating to
YTD 2020/09 figures and YTD PY*



THANK YOU
FOR YOUR ATTENTION!

CONTACT

Investor Relations

T +49 8621 86-2888

F +49 8621 86-502888

ir@alzchem.com

WWW.ALZCHEM.COM

AGENDA

Analyst Presentation Q3/2020



EXECUTIVE SUMMARY

BUSINESS AND FINANCIAL DETAILS

BACK-UP

BALANCE SHEET

AlzChem Group




ALZCHEM GROUP (IN T€)	31.12.2019	30.09.2020	Deviation	
Intangible assets	1,541	1,311	-230	-14.9%
Tangible assets	165,702	164,475	-1,227	-0.7%
Investment properties				
Right of use (assets)	9,770	8,344	-1,426	-14.6%
Investments accounted for using the equity				
Financial assets	20	20		
Trade receivables				
Other receivables	470	527	57	12.1%
<i>there of Deferred tax assets for pensions</i>				
Deferred tax assets	34,477	35,420	943	2.7%
SUM NON-CURRENT ASSETS	211,981	210,098	-1,883	-0.9%
Inventories	74,607	73,582	-1,025	-1.4%
Trade receivables	32,501	32,075	-427	-1.3%
Financial assets	0	0	0	2.3%
Other receivables	14,051	13,295	-756	-5.4%
Income tax receivables	381	816	435	114.3%
Cash and cash equivalents	9,061	12,609	3,548	39.2%
Assets classified as held for sale				
Other assets				
SUM CURRENT ASSETS	130,602	132,378	1,776	1.4%
SUM ASSETS	342,583	342,476	-107	0.0%

ALZCHEM GROUP (IN T€)	31.12.2019	30.09.2020	Deviation	
Share capital	101.763	101.763		
RETAINED EARNINGS (+) / LOSS (-)	69.294	76.512	7.218	10.4%
Other comprehensive income	-48.152	-52.837	-4.685	9.7%
SHARE TO THE SHAREHOLDERS	59.757	62.290	2.533	4.2%
Non-controlling interests	1.592	1.721	128	8.1%
SUM EQUITY	61.350	64.011	2.661	4.3%
Provisions for pensions	134.629	141.533	6.904	5.1%
Other provisions	22.404	23.998	1.594	7.1%
Loans	50.747	42.116	-8.631	-17.0%
Finance lease liabilities	7.710	6.629	-1.081	-14.0%
Trade liabilities				
Other liabilities	513	513		
Deferred tax liabilities	4.745	4.379	-366	-7.7%
SUM NON-CURRENT LIABILITIES	220.748	219.168	-1.580	-0.7%
Other provisions	1.732	1.584	-149	-8.6%
Loans	11.935	15.658	3.723	31.2%
Finance lease liabilities	1.706	1.498	-208	-12.2%
Finance liabilities		0	0	
Trade liabilities	24.069	17.832	-6.237	-25.9%
Other liabilities	19.172	22.144	2.971	15.5%
Income tax liabilities	1.870	582	-1.288	-68.9%
SUM CURRENT LIABILITIES	60.485	59.297	-1.189	-2.0%
Sum EQUITY AND LIABILITIES	342.583	342.476	-107	0.0%

PENSION ACCOUNTING (IFRS)

AlzChem Group (M€)



COMMENTS

- Adjustment of market interest rate from 0.90% → 0.70% increased provision
- Continued low cash payments

INCOME STATEMENT

AlzChem Group



ALZCHEM GROUP (IN T€)	Q1 2019	Q2 2019	Q3 2019	Q4 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	Deviation (Q3)	YTD Sep. 19	YTD Sep. 20	Dev. YOY
Revenue	92,123	96,120	99,431	88,398	94,740	102,511	81,373		-18,058 -18%	287,674	278,624	-9,050 -10%
Increase (+) / Decrease (-) in inventories of finished goods	7,895	-321	-11,883	-553	2,152	-3,162	3,295		15,178 -128%	-4,308	2,286	6,594 -1192%
Other income	4,427	6,114	3,670	2,936	2,425	2,648	2,732		-938 -26%	14,211	7,805	-6,406 -218%
Raw materials and consumables used	-39,541	-38,320	-33,416	-31,112	-35,491	-35,253	-29,903		3,513 -11%	-111,278	-100,647	10,631 -34%
Employee benefits expense	-30,666	-31,497	-29,313	-30,614	-32,509	-31,733	-29,033		280 -1%	-91,475	-93,275	-1,800 6%
Other expense	-21,007	-17,473	-14,925	-20,395	-19,002	-18,190	-16,477		-1,552 10%	-53,405	-53,669	-264 1%
EBITDA	13,231	14,623	13,564	8,659	12,315	16,822	11,986		-1,578 -12%	41,418	41,123	-295 -3%
Depreciation expense	-4,297	-4,302	-4,964	-5,930	-5,582	-5,742	-5,669		-705 14%	-13,563	-16,992	-3,430 58%
Impairment												
EBIT	8,934	10,321	8,601	2,730	6,734	11,080	6,318		-2,283 -27%	27,856	24,131	-3,725 -136%
Investment income	8	54	26	14	5	20	103		77 294%	88	128	40 294%
Other interest and similar income	37	55	24	84	620	-453	14		-10 -42%	116	181	65 78%
Other interest and similar expense	-1,214	-1,537	-2,359	-287	-874	-925	-1,088		1,271 -54%	-5,109	-2,887	2,222 -774%
Financial result	-1,169	-1,428	-2,309	-190	-248	-1,358	-971		1,338 -58%	-4,905	-2,577	2,328 -1228%
Result from associates												
Result from ordinary business	7,766	8,893	6,292	2,540	6,485	9,721	5,347		-945 -15%	22,951	21,554	-1,397 -55%
Taxes on income and profit	-2,212	-2,510	-1,242	-1,381	-2,063	-2,970	-1,542		-300 24%	-5,964	-6,575	-610 44%
<i>thereof income tax</i>	-2,034	-2,653	-1,651	-1,592	-1,630	-3,300	-1,241		410 -25%	-6,337	-6,171	166 -10%
<i>thereof change from deferred taxes</i>	-179	143	409	211	-433	330	-301		-710 -174%	373	-403	-776 -367%
Annual result	5,553	6,383	5,050	1,159	4,422	6,752	3,805		-1,246 -25%	16,986	14,979	-2,008 -173%
<i>thereof minority interests</i>	43	43	43	43	43	43	43			128	128	
<i>thereof shares held by shareholders</i>	5,510	6,340	5,008	1,116	4,380	6,709	3,762		-1,246 -25%	16,858	14,851	-2,008 -180%
Result per share in EUR	0.54 €	0.62 €	0.49 €	0.11 €	0.43 €	0.66 €	0.37 €	- €		1.66 €	1.46 €	

INCOME STATEMENT

AlzChem Group



ALZCHEM GROUP (IN T€)

	Q3 2019	Q3 2020	Deviation (QoQ)		YTD Sep.2019	YTD Sep.2020	Deviation (YoY)	
Revenue	99,431	81,373	-18,058	-18.2%	287,674	278,624	-9,050	-3.1%
Increase (+) / Decrease (-) in inventories of finished goods and work in progress	-11,883	3,295	15,178	-127.7%	-4,308	2,286	6,594	-153.1%
Other income	3,670	2,732	-938	-25.6%	14,211	7,805	-6,406	-45.1%
Raw materials and consumables used	-33,416	-29,903	3,513	-10.5%	-111,278	-100,647	10,631	-9.6%
Employee benefits expense	-29,313	-29,033	280	-1.0%	-91,475	-93,275	-1,800	2.0%
Other expense	-14,925	-16,477	-1,552	10.4%	-53,405	-53,669	-264	0.5%
EBITDA	13,564	11,986	-1,578	-11.6%	41,418	41,123	-295	-0.7%
Depreciation expense	-4,964	-5,669	-705	14.2%	-13,563	-16,992	-3,430	25.3%
Impairment	0	0	0		0	0	0	
EBIT	8,601	6,318	-2,283	-26.5%	27,856	24,131	-3,725	-13.4%
Investment income	26	103	77	294.1%	88	128	40	45.8%
Other interest and similar income	24	14	-10	-41.5%	116	181	65	56.0%
Other interest and similar expense	-2,359	-1,088	1,271	-53.9%	-5,109	-2,887	2,222	-43.5%
Financial result	-2,309	-971	1,338	-57.9%	-4,905	-2,577	2,328	-47.5%
Result from associates	0	0	0		0	0	0	
Result from ordinary business	6,292	5,347	-945	-15.0%	22,951	21,554	-1,397	-6.1%
Taxes on income and profit	-1,242	-1,542	-300	24.2%	-5,964	-6,575	-610	10.2%
<i>thereof income tax</i>	-1,651	-1,241	410	-24.8%	-6,337	-6,171	166	-2.6%
<i>thereof change from deferred taxes</i>	409	-301	-710	-173.6%	373	-403	-776	-208.1%
Annual result	5,050	3,805	-1,246	-24.7%	16,986	14,979	-2,008	-11.8%
<i>thereof minority interests</i>	43	43	0	0.0%	128	128	0	0.0%
<i>thereof shares held by shareholders</i>	5,008	3,762	-1,246	-24.9%	16,858	14,851	-2,008	-11.9%
Result per share in EUR	0.50 €	0.37 €	0	-24.7%	1.67 €	1.47 €	0	-11.8%

CASH FLOW

AlzChem Group



CASHFLOW (IN M€)

	Q3 2019	Q3 2020	1 - 9 2019	1 - 9 2020
Consolidated earnings before taxes	6,292	5,347	22,951	21,554
Depreciation on fixed and intangible assets	4,964	5,669	13,563	16,992
Decrease in pension provisions	-227	-266	-770	-901
Loss (+) / Profit (-) from the sale of non-current assets	-2	-2	-14	-3
Other non-cash income (-) and expenses (+)	2,468	1,100	8,285	2,572
Financial result	2,309	971	4,905	2,577
Interests & Taxes	-2,563	-3,095	-5,072	-9,359
Increase (+) / Decrease (-) Net Working Capital	9,675	12,352	-18,276	354
Cashflow from ongoing operations (Net cash flow)	22,915	22,075	25,570	33,786
Cash outflows for investments in fixed assets	-9,685	-6,406	-32,276	-16,029
Cash inflows from the sale of fixed assets	2	3	51	5
Cash inflow from the acquisition / Reverse acquisition				
Cashflow from investing activity	-9,683	-6,403	-32,225	-16,025
Free cashflow	13,232	15,672	-6,655	17,762
Deposits (+) / Repayment (-) bank loans long-term			30,102	
Repayment of bank loans long-term	-2,157	-2,984	-3,959	-8,951
Deposits (+) / Repayment (-) from short-term financing lines	-14,831	-9,653	-12,067	4,000
Dividend payments	-9,159		-9,159	-7,632
Payment of reduction in leasing liabilities	-392	-454	-1,120	-1,386
Payment of transaction costs of capital increases				
Payments to non-controlling interests			-171	-171
Cashflow from financing activity	-17,381	-13,090	3,627	-14,139
Net increase / decrease in cash and cash equivalents	-4,148	2,582	-3,028	3,623

SEGMENT OVERVIEW BY QUARTER

AlzChem Group



SALES	2018				2019				2020				Deviation PY (Q3)		YTD Q3 2020		Deviation PY (YOY)	
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	T€	%	PY T€	Actual T€	T€	%
Basics & Intermediates	34.155	36.926	35.896	32.989	35.465	37.844	41.693	34.405	36.012	38.266	32.320		-9.374	-29%	115.003	106.598	-8.405	-7%
Specialty Chemicals	53.917	56.817	49.805	48.876	50.063	51.686	50.952	47.321	52.199	57.854	42.995		-7.957	-19%	152.700	153.048	348	0%
Other and Holding	6.450	6.971	6.259	6.145	6.595	6.591	6.786	6.672	6.529	6.391	6.058		-727	-12%	19.971	18.978	-993	-5%
Group Consolidation		5					0						0		0		0	-100%
AlzChem Group	94.522	100.719	91.960	88.010	92.124	96.120	99.430	88.398	94.740	102.511	81.373		-18.058	-22%	287.674	278.624	-9.050	-3%

EBITDA	2018				2019				2020				Deviation PY (Q3)		YTD Q3 2020		Deviation PY (YOY)	
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	T€	%	PY T€	Actual T€	T€	%
Basics & Intermediates	1,060	188	106	-2,242	1,038	628	3,220	360	1,903	2,485	2,006		-1,215	-61%	4,887	6,394	1,507	31%
Specialty Chemicals	12,648	16,128	9,485	12,431	11,711	12,919	9,218	7,837	10,158	14,457	9,418		200	2%	33,847	34,033	185	1%
Other and Holding	759	-262	547	-852	357	838	1,435	1,877	317	81	361		-1,074	-298%	2,629	758	-1,871	-71%
Group Consolidation	589	-152	265	-1,341	125	239	-309	-1,414	-63	-201	202		511	253%	55	-62	-117	-213%
AlzChem Group	15,057	15,902	10,402	7,996	13,231	14,623	13,564	8,659	12,315	16,822	11,986		-1,578	-13%	41,418	41,123	-295	-1%

EXECUTIVE TEAM

AlzChem Group AG



KLAUS ENGLMAIER, COO

WITH ALZCHEM SINCE 1988

AREAS OF RESPONSIBILITY Production, Engineering, Environment/Safety/Health/Quality, Technology

ANDREAS NIEDERMAIER, CEO

WITH ALZCHEM SINCE 1999

AREAS OF RESPONSIBILITY Company Strategy, Finance & Controlling, Investor Relations & Communication, IT, Risk Management, HR, Supply Chain Management, Legal/Patents & Trademarks

DR. GEORG WEICHSELBAUMER, CSO


WITH ALZCHEM SINCE 2012

AREAS OF RESPONSIBILITY Marketing, Sales, Innovation Management & Process Development, R&D, Product Safety and Approval




ALZCHEM GROUP LOCATIONS

Production sites and sales companies



Fully Integrated Business Model (“Verbund” System)

Ability to adapt production to satisfy changing end market needs



BENEFITS OF “VERBUND”

- Full control of product quality and specifications
- Lower costs
- Higher financial predictability
- Certainty of supply
- Well positioned to address niche markets
- Economies of scale
- Low carbon footprint

MEGATRENDS AS GROWTH DRIVERS

Growth of the population



Healthy aging



Sustainability






OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries

	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
SPECIALTY CHEMICALS	CREAMINO	A feed additive for broilers and pigs	Feed additive
	Creapure®	Premium brand for creatine monohydrate as a food supplement in sports nutrition	Food supplements
	LIVADUR	Dietary supplement with pure creatine	Food supplements
	Dormex®	Plant growth regulator used in fruit production	Agriculture
	BREATHRU® S 301	Additive for plant protection formulations	Agriculture
	Sitofex®	Plant growth regulator used in fruit production	Agriculture
	Alzogur®	Biocide for the prevention of diseases in animal production	Agriculture
	Silzot® SQ	Silicon nitride powder for the solar industry	Photovoltaics
	Silzot® HQ	Silicon nitride powder for ceramic applications	Ceramics
	Bioselect®	Highly purified form of guanidine hydrochloride salts	Pharmaceuticals / API
	Cyanamide	An organic compound widely used in agriculture and pharmaceuticals	Agriculture and pharmaceuticals
	DYHARD®	Hardeners and accelerators in powder, paste and liquid form	Hardener & Accelerator Systems for Composite Materials
	Thiourea	Various applications incl. flotation agents and pharmaceutical raw materials	Mining and pharmaceuticals
	Nitroguanidine	Intermediates for agrochemical products	Various

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries

	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
BASICS & INTERMEDIATES	 CaD [®]	Calcium carbide-based mixtures for hot metal desulphurization	Steel industry
	Guanidine Salts	Fuel for airbags, key production of the intermediate product	Automotive
	Dicyandiamide	Versatile intermediate in various markets including the pharmaceutical industry	Pharmaceutical Agriculture
	 NITRALZ [®]	Business fields in color, agro and pharmaceutical applications	Pigments Pharmaceutical
	 Perlka [®]	Special calcium cyanamide multi-effect fertilizer	Agriculture
OTHER & HOLDING	Operation of the Trostberg Chemical Park (companies located at the site: AlzChem, BASF, Firmenich, Aramark, VIACTIV, Degussa Bank)		
	Site services		
	Other activities not included in the "Specialty Chemicals" or "Basics & Intermediates" segments		


KEY SHARE DATA

Share Details as of November 9, 2020



SHARES OUTSTANDING	10,176,335
LAST CLOSING PRICE	EUR 18.80
MARKET CAPITALIZATION	EUR 191.3 m
TICKER	ACT
WKN	A2YNT3
ISIN	DE000A2YNT30
LISTING	Frankfurt Stock Exchange – Prime Standard
DESIGNATED SPONSOR	Baader Bank AG Oddo Seydler Bank AG

SHAREHOLDER STRUCTURE



** Information regarding the free float in accordance with section 2.3 of the Guide to the Equity Indices of Deutsche Börse AG, as amended.*